Glycosylation News and Research

RSS

Cellectis, Medicago complete first step in therapeutic protein research collaboration

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus Like Particles, and Cellectis plant sciences, a US-based subsidiary of Cellectis Group, the specialist in genome engineering, today announced the successful completion of the first step in their research collaboration to improve therapeutic proteins produced in tobacco plants.

4 Oct 2012

GlcNAc plays a key role in keeping cancerous monsters ‘fed’

Behaving something like ravenous monsters, tumors need plentiful supplies of cellular building blocks such as amino acids and nucleotides in order to keep growing at a rapid pace and survive under harsh conditions. How such tumors meet these burgeoning demands has not been fully understood.

24 Aug 2012

Osteoarthritis gene tic markers identified

Scientists have used data from the Arthritis Research UK Osteoarthritis Genetics study to identify five gene loci significantly associated with the development of the disease.

10 Jul 2012

New tool should serve as cellular equivalent for children with CDG syndromes

Just as Gotham City uses the Bat Signal to call for Batman's aid, a new tool developed by scientists from the Sanford-Burnham Medical Research Institute in La Jolla, California, should serve as the cellular equivalent for children with glycosylation disorders, sometimes called "CDG syndromes."

13 Jun 2012

Biologists engineer algae to produce potential candidates for malarial vaccine

Biologists at the University of California, San Diego have succeeded in engineering algae to produce potential candidates for a vaccine that would prevent transmission of the parasite that causes malaria, an achievement that could pave the way for the development of an inexpensive way to protect billions of people from one of the world's most prevalent and debilitating diseases. Initial proof-of-principle experiments suggest that such a vaccine could prevent malaria transmission.

17 May 2012

New method uses E. coli bacteria to engineer human therapeutic glycoproteins

Escherichia coli - a bacteria considered the food safety bane of restaurateurs, grocers and consumers - is a friend. Cornell University biomolecular engineers have learned to use E. coli to produce sugar-modified proteins for making pharmaceuticals cheaper and faster.

27 Mar 2012

Whole-exome sequencing discovers cause of glycosylation disorders

Sequencing a patient's entire genome to discover the source of his or her disease is not routine - yet. But geneticists are getting close. A case report, published this week in the American Journal of Human Genetics, shows how researchers can combine a simple blood test with an "executive summary" scan of the genome to diagnose a type of severe metabolic disease.

4 Feb 2012

Researchers successfully treat severe congenital disorder in mouse model

Using a mouse model, Heidelberg University Hospital researchers have for the first time successfully treated a severe congenital disorder in which sugar metabolism is disturbed.

23 Dec 2011

Report shows how mutant gene influences lipid metabolism

People who carry a malfunctioning copy of a particular gene are especially good at clearing fat from their systems. The report in the December Cell Metabolism, a Cell Press publication, shows how the mutant gene influences metabolism in this way.

7 Dec 2011

Nature Biotechnology publishes BGI, GT Life Sciences' study on CHO K1 genome

BGI, the world's largest genomics organization, and GT Life Sciences, Inc., a privately held biotechnology company that utilizes a proven metabolic modeling and experimental platform to drive the discovery and design of new products and processes for the life sciences field, announced today that their collaborative study on the genomic sequence of the Chinese hamster ovary (CHO) K1 cell line was published July 31, 2011 online in Nature Biotechnology.

1 Aug 2011

LFB receives U.S. patent titled 'Monoclonal Antibodies with Enhanced ADCC Function'

LFB announced today that it has been recently issued U.S. Patent 7,931,895 titled "Monoclonal Antibodies with Enhanced ADCC Function" on April 26, 2011, by the U.S. Patent and Trademark Office.

8 Jul 2011

New book on aging

Aging is a natural part of life. From the minute we are born we are heading in one certain direction: towards death. That said, it is possible to arrive at that ultimate destination graceful and vital to our last days rather than chronically ill suffering from one or many debilitating illnesses.

25 Apr 2011

VARI, Gentel Biosciences receive U.S. Patent for new glycan detection technology

Gentel Biosciences, a leader in proteomics tools, and Van Andel Research Institute, a biomedical research institute, jointly announce today the granting of U.S. Patent 7,838,634 for a new method to profile changes in the glycosylation of proteins captured on the surface of an antibody array slide. Gentel first obtained an exclusive right to commercialize the technology in 2006.

25 Mar 2011

Biomarin commences BMN 701 Phase 1/2 trial for treatment of Pompe disease

BioMarin Pharmaceutical Inc. announced today that it has initiated a Phase 1/2 trial for BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase in development for the treatment of Pompe disease.

20 Jan 2011

GT Life Sciences and BGI complete CHO-K1 genome sequencing

GT Life Sciences, a privately held biotechnology company that utilizes a proven metabolic modeling and experimental platform to drive the discovery and design of new products and processes for the life sciences field, and BGI, the largest genomics organization in the world, announced that they have successfully completed for the first time the sequencing of the Chinese hamster ovary genome.

6 Jan 2011

New objective criteria for evaluating hemostatic efficacy in treatment of VWD

Octapharma USA researchers presented new stringent, objective criteria used in the evaluation of hemostatic efficacy in the treatment of von Willebrand disease and reported on their application of these criteria in clinical trials during the recently completed National Hemophilia Foundation Annual Meeting.

9 Dec 2010

CEVEC establishes North American subsidiary in Maryland, USA

CEVEC Pharmaceuticals, the developer of a novel human protein expression system derived from amniocytes, announced today the US expansion of it's business by founding a North American subsidiary, CEVEC Pharmaceuticals, Inc., in Potomac, Maryland, USA.

15 Nov 2010

Researchers investigate Human-cl rhFVIII factor for severe hemophilia A treatment

Octapharma AG, one of the largest human protein products manufacturers in the world, and Octapharma USA today announced that patients diagnosed with severe hemophilia A have started treatment in a multi-center study that is researching the use of the first recombinant Factor VIII (rFVIII) derived from a human cell line (Human-cl rhFVIII).

2 Nov 2010

Octapharma initiates Human-cl rhFVIII clinical study for severe hemophilia A

Octapharma, one of the largest human protein products manufacturers in the world, today announced that patients diagnosed with severe hemophilia A have started treatment with the first recombinant Factor VIII derived from a human cell line (Human-cl rhFVIII). Researchers are investigating pharmacokinetics, efficacy, safety and immunogenicity of Human-cl rhFVIII for previously treated patients with severe hemophilia A.

28 Oct 2010

CAP cells produce high virus titers upon influenza strain infection

CEVEC Pharmaceuticals, the developer of an extremely potent protein expression system based on human CAP cells, announced today that CAP cells produce high virus titers upon infection with influenza strains. The virus titers are as good as or even higher than with MDCK and Vero cells, host cells currently used for influenza vaccine production.

29 Sep 2010